CLOSED
GET A PIECE OF MEDVECTOR - TELEMEDICINE FOR CLINICAL TRIALS
Transforming Clinical Trials
MedVector is an industry-first telemedicine platform that greatly accelerates clinical trials. By connecting subjects from anywhere in the world to existing clinical trial sites, MedVector has proven to exponentially increase clinical trial participation and dramatically accelerate FDA approval. Our service generates revenue for doctors and hospitals, reduces costs to clinical trial sponsors, and brings life-changing, advanced medicine to the market more quickly.
$906,237.52 Raised
REASONS TO INVEST
The Clinical Trials Market is currently worth ~$47 billion, with a predicted value of $104 billion based on our extensive research.
We have one of the world's largest clinical trial networks, obtaining access to 7 hospitals consisting of hundreds of thousands of patients per year.
During our case studies with Novartis, our progress greatly excelled against traditional patient recruitment services. In just 7 weeks we were able to do what often takes years.
ABOUT
HEADQUARTERS
898 N. Pacific Coast Highway
El Segundo , CA 90245
WEBSITE
View Site
MedVector is an industry-first telemedicine platform that greatly accelerates clinical trials. By connecting subjects from anywhere in the world to existing clinical trial sites, MedVector has proven to exponentially increase clinical trial participation and dramatically accelerate FDA approval. Our service generates revenue for doctors and hospitals, reduces costs to clinical trial sponsors, and brings life-changing, advanced medicine to the market more quickly.
TEAM
Scott Stout
CO-FOUNDER / CEO
Dr. Dennis J. Patterson
CO-FOUNDER / SVP MEDICAL AFFAIRS
TERMS
MedVector - Telemedicine for Clinical Trials
Overview
PRICE PER SHARE
$1.45
DEADLINE
Jul. 30, 2021 at 6:59 AM UTC
VALUATION
$10.02M
FUNDING GOAL
$10k - $1.07M
Breakdown
MIN INVESTMENT
$495.90
MAX INVESTMENT
$106,999.85
MIN NUMBER OF SHARES OFFERED
6,896
MAX NUMBER OF SHARES OFFERED
737,931
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
COVID Relief
This offering is being conducted on an expedited basis due to circumstances relating to COVID-19 and pursuant to the SEC’s temporary regulatory COVID-19 relief set out in Regulation Crowdfunding §227.201(z).
Expedited closing sooner than 21 days
In reliance on Regulation Crowdfunding §227.303(g)(2) A funding portal that is an intermediary in a transaction involving the offer or sale of securities initiated between May 4, 2020, and August 31, 2020, in reliance on section 4(a)(6) of the Securities Act (15 U.S.C. 77d(a)(6)) by an issuer that is conducting an offering on an expedited basis due to circumstances relating to COVID-19 shall not be required to comply with the requirement in paragraph (e)(3)(i) of this section that a funding portal not direct a transmission of funds earlier than 21 days after the date on which the intermediary makes publicly available on its platform the information required to be provided by the issuer under §§227.201 and 227.203(a).
Company Perks*
Early Bird
Friends and Family - First 72 hours | 20% bonus shares
Super Early Bird - Next 72 hours | 15% bonus
Early Bird Bonus - Next 7 days | 10% bonus shares
Volume
Tier 1 perk - ($10,000 + 5% bonus shares)
Tier 2 perk - ($25,000+ 10% bonus shares)
Tier 3 perk - ($50,000+ 15% bonus shares)
*All perks occur when the offering is completed.
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.
ALL UPDATES
REWARDS
JOIN THE DISCUSSION
0/2500
Michael Williams
2 years ago
can we get an update?
1
1
Svenne Juul
2 years ago
In your phase 1 - 2 - 3 you describe that in phase 1 you will 'Drive subjects from unapproved locations to approved clinical trial sites.' Why is there a need to drive the subjects when the tele application is 90% done?
1
0
James Florence
2 years ago
Hey Scott! You said at the start of 2021 you expect to start generating revenue Q2 2021, did you all achieve that goal? Or can we get an update on that? Thanks!
3
0
Aron Roberts
2 years ago
"The 20 year clock on the medical patent starts with the first subject in a clinical trial." Could you tell us where that's documented? I'm just a layperson, with no biomed background, but my initial Google searches weren't able to turn that up. Am seeing this on the FDA's site (https://www.fda.gov/drugs/development-approval-process-drugs/frequently-asked-questions-patents-and-exclusivity#howlongpatentterm): "Currently, the term of a new patent is 20 years from the date on which the application for the patent was filed in the United States." And a 2016 paper in a state medical association journal (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6139778/) states similarly (albeit with some possible complexity around "priority dates"): "The patent becomes enforceable for a term that begins on the date the patent is issued, and ends on the date that is 20 years from the earliest priority date (filing date)."
1
1
Michael Williams
3 years ago
Can't believe it's already closing. Might have to make one more investment on this one before the end. I'm very optimistic about the path your on. Telemedicine is going to be critical in trials to come. You're way ahead of the game in my opinion.
1
0
W Kim Colich
3 years ago
Hi Scott, Now with only 5 days left in the campaign, would you please consider lowering the minimum investment amount to the $232-$290 range? This will allow MANY others to join in, and hopefully push you up to your maximum. Thanks for considering. Blessings
1
0
John Chirichiello
3 years ago
How does your company differ from giant Pharma Intelligence/Informa? They have numerous products and platforms supporting clinical trials and data analytics in place that are global.
1
0
James Florence
3 years ago
How does your business differ from Science 37?
1
0
James Florence
3 years ago
Also, I saw on your YouTube update that you had $1.4M in contracts, do you have an updated figure?
1
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
FAQS
Crowdfunding
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
ramesh bas
6 months ago
any one want to buy my shares? is this trading any time soon?
1
0